// App-Quantinova.ai

: Challenges in setting up Phase III idiopathic pulmonary fibrosis studies during the COVID-19 pandemic: Experience from the STARSCAPE program

Researchers

Presenter

  • Luca Richeldi

Principal Investigators

  • Vincent Cottin

  • Lutaf Islam

  • Gisli Jenkins

  • Nikhil Kamath

  • Yoshikazu Inoue

  • Nimesh Parmar

  • Jessie Randhawa

  • Ganesh Raghu

Medical Centers

  • Clinical Research Cente, National Hospital Organization Kinki-Chuo Chest Medical Center, Osaka, Japan,

  • NIHR, Nottingham Biomedical Research Centre, Nottingham University Hospitals, Nottingham, United Kingdom

  • National Reference Center for Rare Pulmonary Diseases, Louis Pradel Hospital, Hospices Civils de Lyon, Claude Bernard University Lyon 1, Lyon, France,

  • Univ of Washington Medical Ctr, Seattle, Washington, United States of America

  • Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Universita Cattolica del Sacro Cuore, Rome, Italy

  • Roche Products Ltd., Welwyn Garden City, United Kingdom

Locations

  • United States

  • United Kingdom

  • Italy

  • France

  • Japan

Companies

  • Feng Chi Biotech Cor

Study Components

Therapeutic Area

  • Pulmonary/Respiratory Diseases

  • Infectious Diseases (ID)

Disease

  • Idiopathic pulmonary fibrosis

  • Coronavirus disease

Biomarkers

  • N/A

Drug/Treatment

  • Pentraxin-2

  • PRM151

Outcome

  • N/A

Study Design

  • N/A

Phase

  • III

Study Id's

  • NCT04552899

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved